Aqueous Humor and Serum Tumor Necrosis Factor-α in Clinical UveitisSantos Lacomba M.a · Marcos Martín C.a · Gallardo Galera J.M.a · Gómez Vidal M.A.d · Collantes Estévez E.b · Ramírez Chamond R.c · Omar M.M.d
aDepartment of Ophthalmology, bDepartment of Rheumatology, and cDepartment of Experimental Medicine, Reina Sofia University Clinic, Cordoba, and dDepartment of Internal Medicine, Ciudad de Jaen University Clinic, Jaen, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Objective: To study the local and systemic behavior of the tumor necrosis factor-α (TNF-α) in patients with active uveitis. Methods: TNF-α levels were measured in aqueous humor and peripheral blood samples using an enzyme-linked immunosorbent assay from 23 patients with uveitis and 16 control patients who had been operated on for uncomplicated cataracts. Results: Aqueous humor and sera of patients with uveitis showed higher levels of TNF-α than those of controls (p < 0.001). A comparison of cytokine levels between aqueous humor and sera showed significantly higher levels of TNF-α in serum than aqueous humor (p < 0.001). Correlation studies using the regression test for successive steps showed that serum TNF-α levels correlated with recurrent uveitis (r = 0.4150; p = 0.0489). Conclusions: TNF-α is a cytokine that participates actively in the pathogenesis of clinical uveitis. Our data emphasize the greater systemic than local participation of TNF-α. Finally, an elevated serum TNF-α seems to be associated with a recurrent pattern of uveitis.
© 2001 S. Karger AG, Basel
- Ongkosuwito JV, Feron EJ, van Doornik CE, Van der Lelij A, Hoyng CB, La Heij EC, Kijlstra A: Analysis of immunoregulatory cytokines in ocular fluid samples from patients with uveitis. Invest Ophthalmol Vis Sci 1998;39:2659–2665.
Rahi AH, Al-Kaff A: Cytokine profile in uveitis: A point prevalence study; in Whitcup SM, Nussenblatt RB, Caspi RR, Gery I (eds): Advances in Ocular Immunology. International Congress Series. Amsterdam, Elsevier Science, 1994, pp 369–372.
- Calder VL, Shaer B, Muhaya M, Mclauchlan M, Pearson RV, Jolly J, Towler HM, Lightman S: Increased CD4+ expression and decreased IL-10 in the anterior chamber in idiopathic uveitis. Invest Ophthalmol Vis Sci 1999;40:2019–2024.
- Murray PI, Hoekzema R, Van Haren MAC, De Hon FD, Kijlstra A: Aqueous humor interleukin-6 levels in uveitis. Invest Ophthalmol Vis Sci 1990;31:917–920.
- Norose K, Yano A, Wang XC, Tokushima T, Umihira J, Seki A, Nohara M, Segawa K: Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 1994;35:33–39.
- Palexas GN, Sussman G, Welsh NH: Ocular and systemic determination of IL-1 beta and tumour necrosis factor in a patient with ocular inflammation. Scand J Immunol Suppl 1992;11:173–175.
- Lee SJ, Li Z, Sherman B, Foster CS: Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 1993;34:3522–3525.
- Franks WA, Limb GA, Standford MR, Ogilvie J, Wolstencroft RA, Chignell AH, Dumonde DC: Cytokines in human intraocular inflammation. Curr Eye Res 1992;11:187–191.
Tracey KJ: Tumor necrosis factor; in Remick DG, Friendland JS (eds): Cytokines in Health and Disease. New York, Dekker, 1997, pp 223–239.
- De Vos AF, Van Haren MAC, Verhagen C, Hoekzema R, Kijlstra A: Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994;35:1100–1106.
- Kasner L, Chan CC, Whitcup SM, Gery I: The paradoxical effect of tumor necrosis factor alpha (TNF-α) in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1993;34:2911–2917.
- Rosenbaum JT, Howes EL, Rubin RM, Samples JR: Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol 1988;133:47–53.
- De Vos AF, Van Haren MAC, Verhagen C, Hoekzema R, Kijlstra A: TNF-induced uveitis in the Lewis rat is associated with intraocular interleukin 6 production. Exp Eye Res 1995;60:199–207.
- Bloch-Michel E, Nussenblatt RB: International uveitis study group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987;103:234–235.
- Kogiso M, Tanouchi Y, Mimura Y, Nagasawa H, Himeno K: Endotoxin-induced uveitis in mice. 1. Induction of uveitis and role of T lymphocytes. Jpn J Ophthalmol 1992;36:281–290.
- Brito BE, O’Rourke LM, Pan Y, Anglin J, Planck SR, Rosenbaum JT: IL-1 and TNF-α receptor-deficient mice show decreased inflammation in an immune complex model of uveitis. Invest Ophthalmol Vis Sci 1990;31:917–920.
- Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J: Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun 1998;11:255–264.
- Feys J, Emond JP, Salvanet-Bouccara A: Interleukine-6 et autres cytokines dans l’humeur aqueuse au cours d’uvéites et d’endophthalmies. J Fr Ophtalmol 1994;17:634–639.
- De Vos AF, Van Haren MAC, Verhagen C, Hoekzema R, Kijlstra A: Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. Exp Eye Res 1995;61:667–675.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.